Ox40L-Ox40 pathway plays distinct roles in regulating Th2 responses but does not determine outcome of cutaneous leishmaniasis caused by Leishmania mexicana and Leishmania major

Experimental Parasitology

Volumn 148, Issue , 2015, Pages 49-55

  Tuladhar, Rashmi ^a   Oghumu, Steve ^a   Dong, Ran ^a   Peterson, Allison ^b   Sharpe, Arlene H ^b   Satoskar, Abhay R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cutaneous leishmaniasis; L.major; L.mexicana; Ox40L Ox40

Indexed keywords

CD134 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; OX40 LIGAND; CYTOKINE; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; INFECTION SENSITIVITY; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LYMPH NODE CELL; MOUSE; NONHUMAN; SKIN LEISHMANIASIS; TH1 CELL; TH2 CELL; ANIMAL; BLOOD; IMMUNOLOGY; METABOLISM; PARASITOLOGY; PATHOGENICITY; PATHOLOGY; VIRULENCE;

LEISHMANIA MAJOR; LEISHMANIA MEXICANA;

ANIMALS; ANTIBODIES, PROTOZOAN; CYTOKINES; FEMALE; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; OX40 LIGAND; RECEPTORS, OX40; TH2 CELLS; VIRULENCE;

EID: 84914810802     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2014.11.002     Document Type: Article

References (32)

1. Akiba H., Miyahira Y., Atsuta M., Takeda K., Nohara C., Futagawa T., et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med 2000, 191:375-380.
2. Alexander J., Kaye P.M. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections. Clin. Exp. Immunol 1985, 61:674-682.
3. Alimohammadian M.H., Darabi H., Ajdary S., Khaze V., Torkabadi E. Genotypically distinct strains of Leishmania major display diverse clinical and immunological patterns in BALB/c mice. Infect. Genet. Evol 2010, 10:969-975.
4. Alvar J., Velez I.D., Bern C., Herrero M., Desjeux P., Cano J., et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012, 7:e35671.
5. Asadpour A., Riazi-Rad F., Khaze V., Ajdary S., Alimohammadian M.H. Distinct strains of Leishmania major induce different cytokine mRNA expression in draining lymph node of BALB/c mice. Parasite Immunol 2013, 35:42-50.
6. Bryson K.J., Wei X.Q., Alexander J. Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania mexicana in BALB/c mice. Microbes Infect 2008, 10:834-839.
7. Buxbaum L.U. Leishmania mexicana infection induces IgG to parasite surface glycoinositol phospholipids that can induce IL-10 in mice and humans. PLoS Negl. Trop. Dis 2013, 7:e2224.
8. Buxbaum L.U., Denise H., Coombs G.H., Alexander J., Mottram J.C., Scott P. Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J. Immunol 2003, 171:3711-3717.
9. Chatelain R., Mauze S., Coffman R.L. Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol 1999, 21:211-218.
10. Chatelain R., Mauze S., Varkila K., Coffman R.L. Leishmania major infection in interleukin-4 and interferon-gamma depleted mice. Parasite Immunol 1999, 21:423-431.
11. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol 2010, 28:57-78.
12. Curry A.J., Chikwe J., Smith X.G., Cai M., Schwarz H., Bradley J.A., et al. OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival. Transplantation 2004, 78:807-814.
13. Fossati-Jimack L., Ioan-Facsinay A., Reininger L., Chicheportiche Y., Watanabe N., Saito T., et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J. Exp. Med 2000, 191:1293-1302.
14. Gramaglia I., Weinberg A.D., Lemon M., Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol 1998, 161:6510-6517.
15. Gupta G., Oghumu S., Satoskar A.R. Mechanisms of immune evasion in leishmaniasis. Adv. Appl. Microbiol 2013, 82:155-184.
16. Herwaldt B.L. Leishmaniasis. Lancet 1999, 354:1191-1199.
17. Ishii N., Ndhlovu L.C., Murata K., Sato T., Kamanaka M., Sugamura K. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses. Eur. J. Immunol 2003, 33:2372-2381.
18. Jember A.G., Zuberi R., Liu F.T., Croft M. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J. Exp. Med 2001, 193:387-392.
19. Liang S.C., Greenwald R.J., Latchman Y.E., Rosas L., Satoskar A., Freeman G.J., et al. PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur. J. Immunol 2006, 36:58-64.
20. McMahon-Pratt D., Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?. Immunol. Rev 2004, 201:206-224.
21. Mohammadi M.R., Zeinali M., Ardestani S.K., Kariminia A. Identification of novel Leishmania major antigens that elicit IgG2a response in resistant and susceptible mice. Korean J. Parasitol 2006, 44:43-48.
22. Mottram J.C., Coombs G.H., Alexander J. Cysteine peptidases as virulence factors of Leishmania. Curr. Opin. Microbiol 2004, 7:375-381.
23. Oghumu S., Lezama-Davila C.M., Isaac-Marquez A.P., Satoskar A.R. Role of chemokines in regulation of immunity against leishmaniasis. Exp. Parasitol 2010, 126:389-396.
24. Pippig S.D., Pena-Rossi C., Long J., Godfrey W.R., Fowell D.J., Reiner S.L., et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J. Immunol 1999, 163:6520-6529.
25. Rosas L.E., Keiser T., Barbi J., Satoskar A.A., Septer A., Kaczmarek J., et al. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Int. Immunol 2005, 17:1347-1357.
26. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol 1991, 147:3149-3155.
27. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol 2002, 2:116-126.
28. Stamm L.M., Satoskar A.A., Ghosh S.K., David J.R., Satoskar A.R. STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur. J. Immunol 1999, 29:2524-2529.
29. Tsukada N., Akiba H., Kobata T., Aizawa Y., Yagita H., Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000, 95:2434-2439.
30. Tuladhar R., Natarajan G., Satoskar A.R. Role of co-stimulation in Leishmaniasis. Int. J. Biol. Sci 2011, 7:1382-1390.
31. Yoshioka T., Nakajima A., Akiba H., Ishiwata T., Asano G., Yoshino S., et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol 2000, 30:2815-2823.
32. Zubairi S., Sanos S.L., Hill S., Kaye P.M. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol 2004, 34:1433-1440.